Cochrane Evidence Synthesis and Methods ►

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.

This is a protocol.

Published:

23 September 2024

Authors:

Zwimpfer TA, Ewald H, Bilir E, Jayawardana M, Appenzeller-Herzog C, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Heinzelmann-Schwarz V, Friedlander M, Bowtell DDL, Garsed DW

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Zwimpfer TA, Ewald H, Bilir E, Jayawardana M, Appenzeller-Herzog C, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Heinzelmann-Schwarz V, Friedlander M, Bowtell DDL, Garsed DW. Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma (Protocol). Cochrane Database of Systematic Reviews 2024, Issue 9. Art. No.: CD015896. DOI: 10.1002/14651858.CD015896.